Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Mythic Therapeutics
Mythic Therapeutics Presents Preclinical Data on MYTX-011, an Investigational cMET-Targeting Antibody-Drug Conjugate (ADC), at the American Association for Cancer Research (AACR) Annual Meeting
April 08, 2024
From
Mythic Therapeutics
Via
Business Wire
Mythic Therapeutics Appoints George Eliades, Ph.D., as President and Chief Executive Officer
March 28, 2024
From
Mythic Therapeutics
Via
Business Wire
Mythic Therapeutics Receives FDA Fast Track Designation for MYTX-011 for Patients with Non-Small Cell Lung Cancer (NSCLC) with cMET Overexpression
September 26, 2023
From
Mythic Therapeutics
Via
Business Wire
Mythic Therapeutics to Present New Preclinical Data on MYTX-011, Investigational cMET-Targeting Antibody-Drug Conjugate (ADC), at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 19, 2023
From
Mythic Therapeutics
Via
Business Wire
Mythic Therapeutics Presents Preclinical Data on Investigational cMET-Targeting Antibody-Drug Conjugate (ADC) MYTX-011 at American Association for Cancer Research (AACR) Annual Meeting
April 18, 2023
From
Mythic Therapeutics
Via
Business Wire
Mythic Therapeutics Announces First Subject Dosed in Phase 1 KisMET-01 Clinical Trial of cMET-Targeting Antibody-Drug Conjugate (ADC) MYTX-011 for the Treatment of Non-Small Cell Lung Cancer (NSCLC)
April 04, 2023
From
Mythic Therapeutics
Via
Business Wire
Gilles Gallant, BPharm, PhD, FOPQ, Receives the George R. Pettit Individual Input to the Field Award for 2022
September 27, 2022
From
Mythic Therapeutics
Via
Business Wire
Mythic Therapeutics Announces Appointment of Gilles Gallant, BPharm PhD FOPQ as Chief Development Officer
August 23, 2022
From
Mythic Therapeutics
Via
Business Wire
Mythic Therapeutics Launches with New Approach to Improving Antibody Drug Conjugate Performance, Backed by $103 Million in Series B Financing
December 15, 2021
From
Mythic Therapeutics
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.